TriSalus Life Sciences Q1 Earnings Call Highlights
TriSalus Life Sciences NASDAQ: TLSI reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device.
Open original source